Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469037 | 0.91 | LMNA (0.56) | ALDH1A1HSD17B10TDP1LMNAHTT | |
| SCHEMBL23686014 | 0.90 | LMNA (0.59) | ALDH1A1HSD17B10LMNAHTTTP53 | |
| SCHEMBL11677845 | 0.90 | LMNA (0.59) | ALDH1A1HSD17B10LMNAHTTTP53 | |
| SCHEMBL1931626 | 0.90 | LMNA (0.59) | ALDH1A1HSD17B10LMNAHTTTP53 | |
| Acetic Acid SCHEMBL28760535 | 0.89 | ALDH1A1 (0.42) | ALDH1A1HSD17B10TDP1LMNAHTT | |
| SCHEMBL30772120 | 0.86 | LMNA (0.40) | ALDH1A1HSD17B10TDP1LMNAHTT | |
| SCHEMBL19127214 | 0.86 | SMN1; SMN2 (0.50) | ALDH1A1HSD17B10TDP1LMNAHTT | |
| SCHEMBL11158116 | 0.83 | CYP2C9 (0.56) | ALDH1A1LMNAHTTTP53SMN1; SMN2 | |
| SCHEMBL30772119 | 0.79 | ALDH1A1 (0.36) | ALDH1A1HSD17B10TDP1LMNAHTT | |
| SCHEMBL17897401 | 0.79 | APOBEC3A (0.50) | LMNAHTTTP53SMN1; SMN2APOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-08-19 | — | — | US | disclosed |
| US-20240254083-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4337206-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117659017-A | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2024-03-08 | — | — | CN | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| US-20230099912-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-03-30 | — | — | US | disclosed |
| EP-3747866-B1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | INST MATERIA MEDICA CAMS (CN) | 2023-03-01 | — | — | EP | disclosed |
| US-11518744-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-1539662-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014825-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030232859-A1 | Cannabinoid receptor ligands | SCHERING CORPORATION | 2003-12-18 | — | — | US | disclosed |
| EP-1368308-A1 | CANNABINOID RECEPTOR LIGANDS | Schering Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002062750-A9 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORP (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030096844-A1 | Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity | SCHERING CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2002062750-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0633259-B1 | Sulfonylaminopyrimidines, their preparation and their use as medicine | HOFFMANN LA ROCHE (CH) | 1999-01-13 | — | — | EP | disclosed |
| US-5541186-A | ENDOTHELIN RECEPTOR INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0633259-A1 | Sulfonylaminopyrimidines, their preparation and their use as medicine | F. HOFFMANN-LA ROCHE AG (CH) | 1995-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | FPR1, FPR2, FPR3 | ALDH1A1 3680/4885HSD17B10 2748/4885TDP1 3535/4885 |
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | JAK2, STAT3, STAT5A | ALDH1A1 635/4885HSD17B10 2387/4885TDP1 4486/4885 |
| US-20240254083-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | TRPM2, TRPM7, TRPM8 | ALDH1A1 2748/4885HSD17B10 3856/4885TDP1 2769/4885 |
| US-20230099912-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | JAK2, STAT3, STAT5A | ALDH1A1 635/4885HSD17B10 2387/4885TDP1 4486/4885 |
| US-20030096844-A1 | Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity | SULT2A1, NFKBIA, SULT1A1 | ALDH1A1 85/4885HSD17B10 1874/4885TDP1 958/4885 |
| US-20030232859-A1 | Cannabinoid receptor ligands | CNR1, CNR2, GPR18 | ALDH1A1 1021/4885HSD17B10 1902/4885TDP1 2917/4885 |
| US-11518744-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | JAK2, STAT3, STAT5A | ALDH1A1 635/4885HSD17B10 2387/4885TDP1 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.